AZN Share Price

Open 5481.00 Change Price %
High 5481.00 1 Day -107.00 -1.94
Low 5400.00 1 Week 117.00 2.21
Close 5401.00 1 Month 216.00 4.17
Volume 1955423 1 Year 1369.50 33.97
52 Week High 5520.00
52 Week Low 3994.50
AZN Important Levels
Resistance 2 5476.09
Resistance 1 5445.15
Pivot 5427.33
Support 1 5356.86
Support 2 5325.91
LON UK Most Active Stocks
CWC 74.60 0.27%
CWC 74.60 0.27%
CWC 74.60 0.27%
INC 0.04 -20.00%
GWMO 1.98 -12.00%
IRG 0.40 -9.09%
IRG 0.40 -9.09%
IRG 0.40 -9.09%
IRG 0.40 -9.09%
IRG 0.40 -9.09%
More..
LON UK Top Gainers Stocks
AKT 28.50 5177.78%
HHR 58.00 900.00%
MLD 10.00 700.00%
BAF 95.00 93.88%
BAF 95.00 93.88%
BAF 95.00 93.88%
MES 0.28 75.00%
MES 0.28 75.00%
MES 0.28 75.00%
PFLM 5.75 64.29%
More..
LON UK Top Losers Stocks
ENDV 0.02 -99.85%
KEA 0.10 -91.30%
ACU 0.05 -87.50%
ACU 0.05 -87.50%
ACU 0.05 -87.50%
DCP 0.50 -75.61%
PCI 3.50 -53.27%
PCI 3.50 -53.27%
BHR 0.02 -33.33%
NBR 0.25 -24.24%
More..

AstraZeneca PLC (LON: AZN)

AZN Technical Analysis 5
As on 23rd Jun 2017 AZN Share Price closed @ 5401.00 and we RECOMMEND Strong Buy for LONG-TERM with Stoploss of 4765.06 & Strong Buy for SHORT-TERM with Stoploss of 5013.00 we also expect STOCK to react on Following IMPORTANT LEVELS.
AZN Target for June
1st Target up-side 5639.53
2nd Target up-side 5923.78
3rd Target up-side 6208.03
1st Target down-side 4828.47
2nd Target down-side 4544.22
3rd Target down-side 4259.97
AZN Other Details
Segment EQ
Market Capital 0.00
Sector Healthcare
Industry Drug Manufacturers - Major
Offical website http://www.astrazeneca.com
AZN Address
AZN
2 Kingdom Street
London, W2 6BD
United Kingdom
Phone: 44 20 7604 8000
Fax: 44 20 7604 8151
AZN Latest News
Interactive Technical Analysis Chart AstraZeneca PLC ( AZN LON UK )
Java support must be enabled in order to display FnCharts.
You can download Java from http://www.java.com
Your Comments and Response on AstraZeneca PLC
AZN Business Profile
AstraZeneca PLC is engaged in the discovery, development, and commercialization of medicines for cardiovascular and metabolic disease; oncology; respiratory, inflammation, and autoimmunity; and infection, neuroscience, and gastrointestinal disease areas worldwide. Its principal products include Crestor for the treatment of dyslipidaemia and hypercholesterolemia; Seloken/Toprol-XL for control of hypertension and for use in heart failure and angina; Iressa for non-small cell lung cancer; Faslodex for breast cancer in post-menopausal women; and Zoladex for prostate cancer, breast cancer, and certain benign gynaecological disorders. The company's principal products also comprise Pulmicort for treating asthma and chronic obstructive pulmonary disease (COPD); Symbicort for maintenance treatment of asthma and COPD; Nexium for treatment of acid-related diseases; Seroquel XR for the treatment of schizophrenia, bipolar disorder, major depressive disorder, and generalised anxiety disorder; and Synagis for the prevention of serious lower respiratory tract disease caused by respiratory syncytial virus in paediatric patients. In addition, it has 99 pipeline projects, which include 85 in clinical development and 14 either approved, launched, or filed. The company markets its products to primary care and specialist doctors through distributors or local representative offices. AstraZeneca PLC has collaboration agreements with Amgen, Inc. and FibroGen, Inc. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was founded in 1992 and is headquartered in London, the United Kingdom.